Company news

Beam Therapeutics Inc. news in 2024

Beam Therapeutics Inc.'s news releases, calls and decks from 2024, newest first.

View company

Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

December 16, 2024

Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting

December 7, 2024

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

December 6, 2024

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

December 5, 2024

Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader

December 3, 2024

Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference

November 11, 2024

Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs

November 4, 2024

Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting

November 4, 2024

Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting

October 28, 2024

Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results

August 5, 2024

Beam Therapeutics Announces Transition of Chief Financial Officer

July 14, 2024

Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)

June 25, 2024

Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease

June 13, 2024

Beam Therapeutics to Participate in Jefferies Global Healthcare Conference

May 29, 2024

Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress

May 13, 2024

Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference

May 7, 2024

Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results

May 6, 2024

Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

March 25, 2024

Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences

February 27, 2024

Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones

February 26, 2024

Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

February 4, 2024

Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones

January 7, 2024

Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 1, 2024

Calls in 2024

Decks in 2024